ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,862.10
0.04%
US Tech 100
19,914.80
0.07%
Dow Jones
42,801.68
-0.61%
Brent Oil
73.555
-1.81%
Bitcoin
66,201.03
0.21%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Oric Pharmaceuticals Inc (ORIC) Quote

Oric Pharmaceuticals Inc

Oric Pharmaceuticals Inc (ORIC)

NASDAQ
9.54
0.21
(2.25%)
Closed October 14 4:00PM
Delayed by 15 minutes
9.54
0.00
( 0.00% )
Pre Market: 9:28AM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
9.54
Bid
8.62
Ask
9.90
Volume
1
0.00 Day's Range 0.00
5.34 52 Week Range 16.65
Market Cap
672.975M
Previous Close
9.54
Open
-
Last Trade
1
@
9.54
Last Trade Time
08:24:25
Financial Volume
-
VWAP
-
Average Volume (3m)
452,102
Shares Outstanding
70,542,476
Dividend Yield
-
PE Ratio
-6.68
Earnings Per Share (EPS)
-1.43
Revenue
-
Net Profit
-100.7M

About Oric Pharmaceuticals Inc

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company h... ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101, ORIC-944, ORIC-114, and ORIC-533. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.oricpharma.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Oric Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ORIC. The last closing price for Oric Pharmaceuticals was $9.54. Over the last year, Oric Pharmaceuticals shares have traded in a share price range of $ 5.34 to $ 16.65.

Oric Pharmaceuticals currently has 70,542,476 shares outstanding. The market capitalization of Oric Pharmaceuticals is $672.98 million. Oric Pharmaceuticals has a price to earnings ratio (PE ratio) of -6.68.

Ask ADVFN Intelligence (AI)

ORIC Latest News

More News

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...

October 09 2024
GlobeNewswire Inc.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that...

October 04 2024
GlobeNewswire Inc.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that...

September 06 2024
GlobeNewswire Inc.

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...

August 26 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

August 12 2024
Edgar (US Regulatory)

Form 8-K - Current report

August 12 2024
Edgar (US Regulatory)

ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates

Initiated dosing of ORIC-944 in combinations with NUBEQA® (darolutamide) and ERLEADA® (apalutamide) in the ongoing Phase 1b trial for prostate cancer Entered into clinical trial collaboration and...

August 12 2024
GlobeNewswire Inc.

ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...

August 05 2024
GlobeNewswire Inc.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that...

August 02 2024
GlobeNewswire Inc.

ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

ORIC-944, a potential best-in-class PRC2 inhibitor, is being evaluated in combination with darolutamide and in combination with apalutamide in patients with mCRPC ORIC entered into clinical trial...

July 16 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.040.4210526315799.59.98.963275709.39761169CS
4-0.52-5.168986083510.0612.838.9645238810.34897019CS
12-1.07-10.084825636210.6112.838.1145210210.0733561CS
26-0.24-2.453987730069.7812.836.334737289.3816022CS
523.9370.05347593585.6116.655.344879389.92497377CS
156-6.87-41.864716636216.4118.582.364253777.5464704CS
260-16.46-63.30769230772640.812.3636473411.69170181CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AALAmerican Airlines Group Inc
$ 11.87
(0.00%)
686.65k
AAGRAfrican Agriculture Holdings Inc
$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 65.2884
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.15
(0.00%)
122
AACGATA Creativity Global
$ 0.9999
(0.00%)
183
AALAmerican Airlines Group Inc
$ 11.87
(0.00%)
686.65k
AAGRAfrican Agriculture Holdings Inc
$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 65.2884
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.15
(0.00%)
122
AACGATA Creativity Global
$ 0.9999
(0.00%)
183
GRTSGritstone bio Inc
$ 0.054
(0.00%)
144.14M
ZPTAZapata Computing Holdings Inc
$ 0.077
(0.00%)
120.22M
DBGIDigital Brands Group Inc
$ 0.1598
(0.00%)
31.42M
LIPOLipella Pharmaceuticals Inc
$ 0.4087
(0.00%)
18.77M
ENVBEnveric Biosciences Inc
$ 0.412
(0.00%)
14.55M

ORIC Discussion

View Posts
Monksdream Monksdream 1 month ago
ORIC under $10
👍️0
Monksdream Monksdream 3 months ago
ORIC under $10
👍️0
Monksdream Monksdream 3 months ago
ORIC under $10
👍️0
Monksdream Monksdream 5 months ago
ORIC 10Q due 5/6
👍️0
Monksdream Monksdream 5 months ago
ORIC under $10
👍️0
Monksdream Monksdream 7 months ago
ORIC 10Q due 3/16
👍️0
Monksdream Monksdream 7 months ago
ORIC new 52 week high
👍️0
Monksdream Monksdream 7 months ago
ORIC new 52 week high
👍️0
Monksdream Monksdream 7 months ago
ORIC new 52 week high
👍️0
Monksdream Monksdream 8 months ago
ORIC new 52 weewk high
👍️0
Monksdream Monksdream 9 months ago
ORIC new 52 week high
👍️0
TheFinalCD TheFinalCD 2 years ago
$ORIC LOOKS LIKE $6 COMING
👍️0
makinezmoney makinezmoney 2 years ago
$ORIC: Tapped $5.40....... still got steam

It ain't over yet





GO $ORIC
👍️0
DH112 DH112 2 years ago
Today is green fields
👍️0
TheFinalCD TheFinalCD 2 years ago
Pfizer will pay $4.65 per share for 5,376,344 of Oric's common shares, for a total of $25 million. The companies plan to move the treatment into a Phase 2 clinical trial in combination with elranatamab, Pfizer's investigational treatment of multiple myeloma

https://finance.yahoo.com/news/oric-pharmaceuticals-announces-clinical-development-224800151.html
👍️0
makinezmoney makinezmoney 2 years ago
$ORIC: 5.25 now........................... lets get to $10

I know you can do it babyyyyyyyyyyyyyyyyy


GO $ORIC
👍️0
makinezmoney makinezmoney 2 years ago
$ORIC : Now at 4.90

YESsssssssssssssss............ this is very impressive news with deal with Pfizer.

Me likes it


GO $ORIC
👍️0
crudeoil24 crudeoil24 2 years ago
Shares of Oric Pharmaceuticals Inc. jumped nearly 60% to $4.79 in premarket trading Thursday after the company agreed to sell $25 million in shares to Pfizer Inc.

The clinical-stage oncology company said Wednesday evening that Pfizer has agreed to buy nearly 5.4 million shares of Oric's common stock for $4.65 apiece.

The investment is part of a clinical development collaboration between the two companies on a Phase 2 study examining Oric's ORIC-533 treatment for multiple myeloma, the companies said.

The companies said the collaboration would potentially advance the treatment into a combination study with Pfizer's elranatamab, an investigational treatment for multiple myeloma.


Write to Dean Seal at dean.seal@wsj.com


(END) Dow Jones Newswires

December 22, 2022 07:25 ET (12:25 GMT)
👍️0
makinezmoney makinezmoney 2 years ago
$ORIC: BOOOoommmmmmm........... Pfiizer invests $25Milly in ORIC

Letssssssss goooooooooooooooooo.


Added 5k shares here at 4.30

Great NEWS


https://www.tipranks.com/news/oric-pharmaceuticals-nasdaqoric-stock-spikes-on-pfizer-deal

GO $ORIC
👍️0

Your Recent History

NASDAQ
ORIC
Oric Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved